{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 Non-Serious Abdominal pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 1 Non-Serious Hypoalbuminemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 Non-Serious Hypoalbuminemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 Non-Serious Hypoxia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 2 Non-Serious Pneumonitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 3 Serious and/or Non-Serious Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 Serious and/or Non-Serious Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Serious and/or Non-Serious Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Toxicity was assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. And Grade 5 is death related to adverse event.","groups":[{"description":"Dose Level 1: 400 mcg LMB-100 administered per dose, dose administered on days 1 and 4 of 21-day cycle, cycle 1 in participants with pleural or peritoneal mesothelioma.\n\nThose with pleural or peritoneal mesothelioma receiving intra-tumoral administration of LMB-100 + Ipilimumab for up to 4 cycles.\n\nFor infusion related reactions precaution, all participants will be premedicated 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration with the following medications: Diphenhydramine 25-50 mg by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose), Famotidine 20 mg by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose), and Acetaminophen 650 mg by mouth (PO) or intravenous (IV).\n\nAdditional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.\n\nBiopsy as feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \\& 4 Day 1, and Cycle 4 Day 21 (±7 days).","id":"OG000","title":"Dose Level 1: 400 mcg LMB-100"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Median follow-up: 3.4 months (1.9 months and 5.0 months)","title":"Number of Participants Who Experienced Grades 1-5 Serious and/or Non-serious Toxicity Related (= Possibly + Probably + Definitely) to Ipilimumab","type":"PRIMARY","unitOfMeasure":"Participants"}